Masanori Koide

List of Publications by Year
in descending order

32 papers	1,431 citations	430874 18 h-index	414414 32 g-index
32 all docs	32 docs citations	32 times ranked	1904 citing authors

#	Article	IF	Citations
1	Osteoclast differentiation by RANKL and OPG signaling pathways. Journal of Bone and Mineral Metabolism, 2021, 39, 19-26.	2.7	293
2	The Regulation of Bone Metabolism and Disorders by Wnt Signaling. International Journal of Molecular Sciences, 2019, 20, 5525.	4.1	214
3	Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. Journal of Periodontal Research, 1997, 32, 524-529.	2.7	134
4	Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss. Journal of Bone and Mineral Research, 2009, 24, 1194-1205.	2.8	103
5	Dendritic cellâ€“based immunotherapy targeting Wilmsâ€™ tumor 1 in patients with recurrent malignant glioma. Journal of Neurosurgery, 2015, 123, 989-997.	1.6	74
6	A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE, 2017, 12, e0181126.	2.5	68
7	Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts. Journal of Bone and Mineral Research, 2017, 32, 2074-2086.	2.8	55
8	Osteoprotegerin-Deficient Male Mice as a Model for Severe Alveolar Bone Loss: Comparison With RANKL-Overexpressing Transgenic Male Mice. Endocrinology, 2013, 154, 773-782.	2.8	48
9	The regulation of osteoclast differentiation by Wnt signals. BoneKEy Reports, 2015, 4, 713.	2.7	47
10	Osteoclastic bone resorption induced by innate immune responses. Periodontology 2000, 2010, 54, 235-246.	13.4	46
11	Wnt16 regulates osteoclast differentiation in conjunction with Wnt5a. Biochemical and Biophysical Research Communications, 2015, 463, 1278-1283.	2.1	39
12	Diphenylhydantoin Inhibits Osteoclast Differentiation and Function Through Suppression of NFATc1 Signaling. Journal of Bone and Mineral Research, 2009, 24, 1469-1480.	2.8	36
13	Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells. Journal of Immunology, 2012, 188, 1772-1781.	0.8	36
14	Regulatory mechanisms of sclerostin expression during bone remodeling. Journal of Bone and Mineral Metabolism, 2019, 37, 9-17.	2.7	32
15	Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS ONE, 2017, 12, e0184904.	2.5	31
16	Roles of cathelicidinâ€related antimicrobial peptide in murine osteoclastogenesis. Immunology, 2013, 140, 344-351.	4.4	28
17	Cytokine Regulation and the Signaling Mechanism of Osteoclast Inhibitory Peptide-1 (OIP-1/hSca) to Inhibit Osteoclast Formation. Journal of Bone and Mineral Research, 2003, 18, 458-465.	2.8	22
18	Prostaglandin E2 receptor EP4-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. European Journal of Pharmacology, 2011, 650, 396-402.	3.5	20

#	Article	IF	Citations
19	The relationship between calcium accumulation in osteoclast mitochondrial granules and bone resorption. Bone, 2009, 45, 980-986.	2.9	18
20	Sclerostin expression in trabecular bone is downregulated by osteoclasts. Scientific Reports, 2020, 10, 13751.	3.3	17
21	Actinobacillus actinomycetemcomitans Y4 capsular polysaccharide induces IL-1beta mRNA expression through the JNK pathway in differentiated THP-1 cells. Clinical and Experimental Immunology, 2005, 141, 261-269.	2.6	11
22	ILâ€12 stimulates the osteoclast inhibitory peptideâ€1 (OIPâ€1/hSca) gene expression in CD4+ T cells. Journal of Cellular Biochemistry, 2009, 107, 104-111.	2.6	11
23	Identification of the Functional Domain of Osteoclast Inhibitory Peptide-1/hSca. Journal of Bone and Mineral Research, 2002, 17, 111-118.	2.8	10
24	Minocycline to be used a potential anti-bone resorption agents due to the suppression of osteoclastic bone resorption. Journal of Oral Biosciences, 2013, 55, 16-22.	2.2	7
25	Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerinâ€Deficient Mice. Journal of the American Heart Association, 2022, 11, e025336.	3.7	7
26	Positive and Negative Regulators of Sclerostin Expression. International Journal of Molecular Sciences, 2022, 23, 4895.	4.1	7
27	The W9 peptide directly stimulates osteoblast differentiation via RANKL signaling. Journal of Oral Biosciences, 2017, 59, 146-151.	2.2	6
28	Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice. Bone, 2022, 160, 116401.	2.9	5
29	Blockade of the angiotensin II type 1 receptor increases bone mineral density and left ventricular contractility in a mouse model of juvenile Paget disease. European Journal of Pharmacology, 2019, 859, 172519.	3.5	3
30	Lipopolysaccharide-Mediated Enhancement of Bone Metabolism in Estrogen-Deficient Mice. Journal of Periodontology, 2008, 79, 2173-2181.	3.4	1
31	Effects of shokyo (Zingiberis Rhizoma) and kankyo (Zingiberis Processum Rhizoma) on prostaglandin E₂ production in lipopolysaccharide-treated mouse macrophage RAW264.7 cells. PeerJ, 2019, 7, e7725.	2.0	1
32	Inhibitor of protein kinase N3 suppresses excessive bone resorption in ovariectomized mice. Journal of Bone and Mineral Metabolism, 2022, 40, 251-261.	2.7	1